1. Home
  2. ACCL vs EVAX Comparison

ACCL vs EVAX Comparison

Compare ACCL & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acco Group Holdings Limited Ordinary Shares

ACCL

Acco Group Holdings Limited Ordinary Shares

N/A

Current Price

$2.29

Market Cap

26.9M

ML Signal

N/A

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$2.79

Market Cap

23.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACCL
EVAX
Founded
2009
2008
Country
Hong Kong
Denmark
Employees
22
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.9M
23.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ACCL
EVAX
Price
$2.29
$2.79
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
24.6K
13.1K
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
$17.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.23
$2.52
52 Week High
$5.00
$12.15

Technical Indicators

Market Signals
Indicator
ACCL
EVAX
Relative Strength Index (RSI) 79.16 36.10
Support Level $1.31 N/A
Resistance Level $2.34 $3.61
Average True Range (ATR) 0.11 0.14
MACD 0.02 0.00
Stochastic Oscillator 88.04 14.42

Price Performance

Historical Comparison
ACCL
EVAX

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: